Article Sidebar

PDF
Issue: Vol. 563 No. 2 (2026)
Section: Các bài báo
DOI: 10.51298/vmj.v563i2.18960
Date Published: 05/10/2026
Views 30
Downloads 18
How to Cite
Phạm, M. Đ., & Ngô, X. T. (2026). CONTEMPORARY ROLE OF CYTOREDUCTIVE NEPHRECTOMY IN METASTATIC RENAL CELL CARCINOMA. Vietnam Medical Journal, 563(2). https://doi.org/10.51298/vmj.v563i2.18960

CONTEMPORARY ROLE OF CYTOREDUCTIVE NEPHRECTOMY IN METASTATIC RENAL CELL CARCINOMA

Minh Đức Phạm1,2, , Xuân Thái Ngô1,2
1 Bệnh viện Chợ Rẫy, TP. Hồ Chí Minh
2 Bộ môn Tiết Niệu Học, Đại học Y Dược TP. Hồ Chí Minh

Main Article Content

Abstract

Objective: Radical nephrectomy has been the standard of care for Renal cell carcinoma (RCC) across all disease stages, the advent of targeted therapies and immune checkpoint inhibitors has reshaped the therapeutic landscape. This review aims to evaluate the evolving role of surgery in the management of metastatic RCC (mRCC) in the context of contemporary systemic therapies.


Methods: We conducted a narrative review of pivotal clinical trials and high-impact studies, along with current treatment guidelines from major urological and oncological societies, to synthesize the latest evidence regarding surgical and systemic treatment strategies in mRCC.


Results: Surgery remains an integral component of RCC management, which should be individualized. In the era of targeted therapy, deferred cytoreductive nephrectomy has demonstrated clinical benefit in selected patients who exhibit favorable responses to systemic treatment. Furthermore, in patients achieving no evidence of disease following metastasectomy or cytoreductive surgery, adjuvant immunotherapy has been associated with improved survival outcomes.


Conclusion: Optimal integration of surgery with targeted therapy and immunotherapy can enhance survival in patients with metastatic disease when applied in carefully selected individuals and at an appropriate therapeutic time point.

Keywords

cytoreductive nephrectomy, metastatic renal cell carcinoma, targeted therapy, immune checkpoint inhibitors

Article Details

References

1. Heng DY, Wells JC, Rini BI, et al. (2014), “Cytoreductive nephrectomy in patients with synchronous metastases from renal cell carcinoma: results from the International Metastatic Renal Cell Carcinoma Database Consortium”, Eur Urol, Vol. 66(4), pp. 704-10.
2. Bex A, Mulders P, Jewett M, et al. (2019), “Comparison of Immediate vs Deferred Cytoreductive Nephrectomy in Patients With Synchronous Metastatic Renal Cell Carcinoma Receiving Sunitinib: The SURTIME Randomized Clinical Trial”, JAMA Oncology, Vol. 5(2), pp. 164-170.
3. Bhindi B HE, Mason RJ, Costello BA, Pagliaro LC, Thompson RH (2018), “Comparative Survival following Initial Cytoreductive Nephrectomy versus Initial Targeted Therapy for Metastatic Renal Cell Carcinoma”, Journal of Urology, Vol. 200(3), pp. 528–34.
4. Choueiri TK, Tomczak P, Park SH, et al. (2024), “Overall Survival with Adjuvant Pembrolizumab in Renal-Cell Carcinoma”, Vol. 390(15), pp. 1359-1371.
5. Dahm P, Ergun O, Uhlig A, et al. (2024), “Cytoreductive nephrectomy in metastatic renal cell carcinoma”, Cochrane Database of Systematic Reviews, (6).
6. Ljungberg B, Bex A, Albiges L, et al. (2024), “EAU Guidelines on Renal Cell Carcinoma”, European Association of Urology, pp. 1-105.
7. Méjean A, Ravaud A, Thezenas S, et al. (2018), “Sunitinib Alone or after Nephrectomy in Metastatic Renal-Cell Carcinoma”, Vol. 379(5), pp. 417-427.
8. Motzer RJ, Barrios CH, Kim TM, et al. (2014), “Phase II Randomized Trial Comparing Sequential First-Line Everolimus and Second-Line Sunitinib Versus First-Line Sunitinib and Second-Line Everolimus in Patients With Metastatic Renal Cell Carcinoma”, Vol. 32(25), pp. 2765-2772.